GlassScriptPhysician profile
Palak Pancholi
NPI 1477135382
$954.71
in general payments reported to CMS, 2019-2025
17 companies · $756 in 2025
The $756 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.96 · 2023: $14.73 · 2024: $164 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $202.79 | 2023-2025 | Rexulti, Nuedexta |
| Dexcom, INC. | $167.41 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $159.29 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.13 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.55 | 2024 | Xifaxan |
| Amgen INC. | $45.92 | 2025 | Otezla, Repatha, Evenity |
| Sumitomo Pharma America, INC. | $39.93 | 2025 | Gemtesa |
| Corcept Therapeutics | $39.23 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $34.10 | 2025 | Veozah |
| Almatica Pharma LLC | $30.40 | 2025 | Loreev Xr |
| Vertex Pharmaceuticals Incorporated | $25.62 | 2025 | |
| Neurelis, INC. | $24.49 | 2024 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.96 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.10 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $18.35 | 2025 | Trelegy Ellipta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16.29 | 2025 | Minimed 780g |
| Kowa Pharmaceuticals America, INC. | $15.15 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Palak Pancholi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.